Zurich Cantonal Bank’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Zurich Cantonal Bank’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6,245	Closed	-$470K	–	2938
2022 Q2	$470K	Hold	6,245	–	–	﹤0.01%	1265
2022 Q1	$168K	Sell	6,245 -447	-7%	-$15K	﹤0.01%	2003
2021 Q4	$319K	Buy	6,692 +1,744	+35%	+$78K	﹤0.01%	1773
2021 Q3	$329K	Buy	4,948 +733	+17%	+$52.2K	﹤0.01%	1573
2021 Q2	$329K	Sell	4,215 -483	-10%	-$35.7K	﹤0.01%	1486
2021 Q1	$444K	Sell	4,698 -430	-8%	-$51.1K	﹤0.01%	1307
2020 Q4	$625K	Buy	5,128 +1,402	+38%	+$154K	﹤0.01%	1161
2020 Q3	$326K	Buy	3,726 +2,186	+142%	+$152K	﹤0.01%	1301
2020 Q2	$99K	Hold	1,540	–	–	﹤0.01%	1946
2020 Q1	$69K	Hold	1,540	–	–	﹤0.01%	1801
2019 Q4	$96K	Buy	+1,540	New	+$73.3K	﹤0.01%	1743

Zurich Cantonal Bank's TPTX Position: Q3 2022 in Review

Zurich Cantonal Bank sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 6,245 shares — an estimated $470K sold.

Zurich Cantonal Bank first reported a position in TPTX in Q4 2019 and held it in 11 quarters. The position peaked at $625K in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Zurich Cantonal Bank reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Zurich Cantonal Bank sold 6,245 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $470K.
Zurich Cantonal Bank first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
Zurich Cantonal Bank's Turning Point Therapeutics, Inc. Common Stock position peaked at $625K in Q4 2020.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Zurich Cantonal Bank's 13F filing for Q3 2022, filed 9 Nov 2022.